

Hypoglossal Nerve Stimulation

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Hypoglossal Nerve Stimulation	1
Summary	1
Definitions	2
General Medical Necessity Criteria	2
Surgical Revision, Explant, or Replacement	3
Experimental, Investigational, or Unproven / Not Medically Necessary	3
Applicable Billing Codes	4
References	8
Clinical Guideline Revision / History Information	10

Summary

Plan members with moderate to severe obstructive sleep apnea (OSA) who are unable to tolerate positive airway pressure therapy, hypoglossal nerve stimulation can be an OSA treatment option. The hypoglossal nerve stimulator is an implanted medical device that reduces the occurrence of OSA by electrically stimulating the hypoglossal nerve, which causes tongue movement. This stimulation is timed with breathing to relieve upper airway obstruction. The hypoglossal nerve stimulation system is fully implanted beneath the skin and controlled with a remote, allowing patients to sleep free from devices on the face or in the mouth. The current FDA-approved device is made by Inspire Medical Systems© and has been available since 2014.

Definitions

“Apnea-hypopnea index (AHI)” is the number of apneas and hypopneas per hour of sleep recorded during a sleep study. The AHI commonly determines the severity of sleep apnea. An apnea is defined as the cessation of airflow at the nose and mouth for a minimum of 10 seconds. A hypopnea is an abnormal respiratory event lasting ≥ 10 seconds with $\geq 30\%$ reduction in thoracoabdominal movement or airflow compared to baseline, and with at least a 4% oxygen desaturation from the pre-event baseline.

“Obstructive sleep apnea (OSA)” is a sleep-related breathing disorder that occurs when the muscles relax during sleep, causing soft tissue in the back of the throat to collapse and block the upper airway. This causes a reduced or complete halt in airflow despite an ongoing effort to breathe.

“Positive airway pressure devices” are non-invasive equipment that assists in ventilation by delivering variable pressures of airflow during inspiration and expiration via an oral, nasal, or oronasal mask. They include:

1. Bi-level positive airway pressure (BPAP) devices
2. Continuous positive airway pressure (CPAP) devices
3. Adaptive servo-ventilation (ASV) devices

“Sleep-study testing” is a diagnostic test that is used to diagnose sleep-related disorders by recording a person’s brain waves, blood oxygen levels, heart rate, and breathing during sleep. Two types of sleep-study tests are recognized in the diagnosis of sleep disordered breathing:

1. “Unattended (Home) polysomnography (PSG)” or “home sleep apnea test (HSAT)” is a portable sleep study that can be done at home without the need for a technician on-site to monitor data.
2. “Attended (facility or laboratory) nocturnal polysomnography” is a test performed overnight in a sleep lab or facility that is administered and overseen by a technician.

Medical Necessity Criteria for Clinical Review

General Medical Necessity Criteria

The Plan considers implantable hypoglossal nerve stimulation medically necessary for initial requests to treat moderate to severe obstructive sleep apnea when ONE of the following criteria is met:

1. Pediatric members with Down syndrome who are 13 to 18 years, when ALL of the following are met:
 - a. Apnea hypopnea index (AHI) greater than 10 and less than 50; *and*
 - b. No complete concentric collapse at the soft palate level; *and*
 - c. Contraindication for, or not effectively treated by, adenotonsillectomy; *and*
 - d. Failure of, or inability to tolerate, PAP therapy despite attempts to improve compliance; *and*
 - e. Standard of care followed in considering all other alternative/adjunct therapies; *or*
2. Members 18 years of age or older, when ALL of the following are met:
 - a. The last polysomnography (PSG) was performed within 24 months of first consultation for implant; *and*

- b. Body mass index (BMI) is less than or equal to 40 kg/m²; *and*
- c. Apnea hypopnea index (AHI) is 15 to 100 events per hour; *and*
- d. The member has predominantly obstructive events with central and mixed apneas less than 25% of the total AHI; *and*
- e. Absence of complete concentric collapse at the soft palate level as seen on a drug-induced sleep endoscopy (DISE) procedure, *and*
- f. No contraindications or anatomical findings that would compromise performance of the device; *and*
- g. Tried and failed, or intolerant to, positive airway pressure (PAP) therapy, defined by ONE of the following:
 - i. AHI is still greater than 15 events per hour despite PAP usage; *or*
 - ii. Inability to use PAP for more than 4 hours per night, 5 nights per week; *or*
 - iii. Unwilling to use PAP machine after attempting to use it; *and*
- h. The device is FDA-approved (e.g., Inspire II System Model 3024, Inspire IV Model 3028 system).

Surgical Revision, Explant, or Replacement

The Plan considers the revision, explant, or replacement of implantable hypoglossal nerve stimulation medically necessary when ONE of the following criteria are met:

- 1. FDA-approved implantable upper airway hypoglossal nerve stimulation device needs repositioning; *or*
- 2. FDA-approved implantable upper airway hypoglossal nerve stimulation device, generator battery and/or leads need replacement because they no longer function or the device is no longer under warranty; *or*
- 3. The remote for the FDA-approved implantable upper airway hypoglossal nerve stimulation device needs replacement because it no longer functions and is no longer under warranty.

Experimental, Investigational, or Unproven / Not Medically Necessary

The Plan considers implantable hypoglossal nerve stimulation experimental, investigational, or unproven for any other indication not listed in this guideline. The Plan considers any non-FDA approved device for implantable hypoglossal nerve stimulation experimental or investigational.

Applicable Billing Codes

Table 1	
Hypoglossal Nerve Stimulation	
CPT/HCPCS codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
31575	Laryngoscopy, flexible; diagnostic
61886	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode arrays
61888	Revision or removal of cranial neurostimulator pulse generator or receiver
64582	Open implantation of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array
64583	Revision or replacement of hypoglossal nerve neurostimulator array and distal respiratory sensor electrode or electrode array, including connection to existing pulse generator
64584	Removal of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array
64585	Revision or removal of peripheral neurostimulator electrode array
92502	Otolaryngologic examination under general anesthesia
92511	Nasopharyngoscopy with endoscope (separate procedure)
95970	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain, cranial nerve, spinal cord, peripheral nerve, or sacral nerve, neurostimulator pulse generator/transmitter, without programming

Table 1	
Hypoglossal Nerve Stimulation	
CPT/HCPCS codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
95976	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional
95977	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional
C1767	Generator, neurostimulator (implantable), non-rechargeable
C1778	Lead, neurostimulator (implantable)
C1787	Patient programmer, neurostimulator
C1820	Generator, neurostimulator (implantable), with rechargeable battery and charging system.
C1826	Generator, neurostimulator (implantable), includes closed feedback loop leads and all implantable components, with rechargeable battery and charging system
C1827	Generator, neurostimulator (implantable), non-rechargeable, with implantable stimulation lead and external paired stimulation controller
C8007	Open implantation of hypoglossal nerve neurostimulator array and pulse generator, not requiring insertion of a separate distal respiratory sensor electrode or electrode array
C8008	Revision or replacement of hypoglossal nerve neurostimulator array including connection to existing pulse generator

Table 1	
Hypoglossal Nerve Stimulation	
CPT/HCPCS codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
C8009	Removal of hypoglossal nerve neurostimulator array and pulse generator
C8011	Open implantation of hypoglossal nerve(s) neurostimulator electrode array(s) and receiver, including external power source and all system components
C8012	Revision or replacement of hypoglossal nerve(s) neurostimulator electrode array(s) and receiver
C8013	Removal of hypoglossal nerve(s) neurostimulator electrode array(s) and receiver
L8680	Implantable neurostimulator electrode, each
L8681	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension
L8688	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension

Table 2	
ICD-10 codes considered medically necessary with Table 1 codes if criteria are met:	
<i>Code</i>	<i>Description</i>
G47.33	Obstructive sleep apnea (adult) (pediatric)
Q90.0 - Q90.9	Down syndrome
Z68.1	Body mass index BMI 19.9 or less, adult
Z68.20 - Z68.29	Body mass index BMI 20-29, adult
Z68.30 - Z68.39	Body mass index BMI 30-39, adult

Table 2	
ICD-10 codes considered medically necessary with Table 1 codes if criteria are met:	
<i>Code</i>	<i>Description</i>
Z68.41	Body mass index [BMI] 40.0-44.9 adult • <u>Due to multiple BMI values represented by this code, clarification is provided below:</u> • When billed for hypoglossal nerve stimulation in members with a BMI of 40.0, it is considered medically necessary

Table 3	
CPT/HCPCS codes considered experimental, investigational, or unproven for indications in this guideline:	
E0492	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application
E0493	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply

Table 4	
ICD-10 codes considered experimental, investigational, or unproven for hypoglossal nerve stimulation:	
<i>Code</i>	<i>Description</i>
G47.30	Sleep apnea, unspecified
G47.31	Primary central sleep apnea
G47.32	High altitude periodic breathing
G47.34	Idiopathic sleep related nonobstructive alveolar hypoventilation
G47.35	Congenital central alveolar hypoventilation syndrome
G47.36	Sleep related hypoventilation in conditions classified elsewhere
G47.37	Central sleep apnea in conditions classified elsewhere
G47.39	Other sleep apnea

Table 4	
ICD-10 codes considered experimental, investigational, or unproven for hypoglossal nerve stimulation:	
<i>Code</i>	<i>Description</i>
Z68.41	Body mass index [BMI] 40.0-44.9, adult • <u>Due to multiple BMI values represented by this code, specific exclusions are indicated:</u> • When billed for hypoglossal nerve stimulation in members with a BMI of 41.0-44.9, it is considered experimental, investigational, or unproven
Z68.42	Body mass index [BMI] 45.0-49.9, adult
Z68.43	Body mass index [BMI] 50.0-59.9, adult
Z68.44	Body mass index [BMI] 60.0-69.9, adult
Z68.45	Body mass index [BMI] 70 or greater, adult

References

1. Alrubasy, W. A., Abuawwad, M. T., Taha, M. J. J., Khurais, M., Sayed, M. S., Dahik, A. M., Keshk, N., Abdelhadi, S., & Serhan, H. A. (2024). Hypoglossal nerve stimulation for obstructive sleep apnea in adults: An updated systematic review and meta-analysis. *Respiratory Medicine*, 234, 107826. <https://doi.org/10.1016/j.rmed.2024.107826>
2. American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). (2021, April 22). *Position Statement: Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnea (OSA)*. Retrieved June 17, 2021 from <https://www.entnet.org/resource/position-statement-hypoglossal-nerve-stimulation-for-treatment-of-obstructive-sleep-apnea-osa/>
3. Chang, J. L., Goldberg, A. N., Alt, J. A., Mohammed, A., Ashbrook, L., Auckley, D., Ayappa, I., Bakhtiar, H., Barrera, J. E., Bartley, B. L., Billings, M. E., Boon, M. S., Bosschieter, P., Braverman, I., Brodie, K., Cabrera-Muffly, C., Caesar, R., Cahali, M. B., Cai, Y., Cao, M., ... Rosen, I. M. (2023). International consensus statement on obstructive sleep apnea. *International Forum of Allergy & Rhinology*, 13(7), 1061–1482. <https://doi.org/10.1002/alr.23079>
4. Cooper, T., Sufyan, A. S., & Aboubakr, S. (2023, July 8). *Hypoglossal stimulation device*. StatPearls - NCBI Bookshelf. <https://www.ncbi.nlm.nih.gov/books/NBK594264/>
5. Costantino, A., Rinaldi, V., Moffa, A., Luccarelli, V., Bressi, F., Cassano, M., Casale, M., & Baptista, P. (2020). Hypoglossal nerve stimulation long-term clinical outcomes: A systematic review and meta-analysis. *Sleep and Breathing*, 24(2), 399–411. <https://doi.org/10.1007/s11325-019-01923-2>

6. Eastwood, P.R., Barnes, M., MacKay, S.G., et al. (2020, Jan). Bilateral hypoglossal nerve stimulation for treatment of adult obstructive sleep apnoea. *Eur Respir J*, 55(1). doi: 10.1183/13993003.01320-2019
7. European Network for Health Technology Assessment (EUnetHTA) OTCA21 Authoring Team. Hypoglossal Nerve Stimulation Systems for Treatment of Obstructive Sleep Apnea: Project ID: OTCA21. Diemen (The Netherlands): EUnetHTA; 2020. p. 90.
8. Gottlieb, D. J., & Punjabi, N. M. (2020). Diagnosis and management of obstructive sleep apnea: a review. *Jama*, 323(14), 1389-1400.
9. Halle TR, Oh MS, Collop NA, et al. Surgical Treatment of OSA on Cardiovascular Outcomes: A Systematic Review. *Chest*. 2017;152(6):1214-29.
10. Hayes, Inc. Hayes Medical Technology Directory Report. *Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnea*. Lansdale, PA: Hayes, Inc.; Annual Review Dec 27, 2023.
11. Inspire Medical Systems. *Physician Billing Guide 2021*. <https://professionals.inspiresleep.com>. Retrieved June 24, 2021 from <https://professionals.inspiresleep.com/wp-content/uploads/sites/3/2021/02/2021-Physician-Billing-Guide.pdf>
12. Kent, D.T., Carden, K.A., Wang, L., et al. (2019, Nov). Evaluation of hypoglossal nerve stimulation treatment in obstructive sleep apnea. *JAMA Otolaryngol Head Neck Surg*, 145(11), 1044-1052. doi: 10.1001/jamaoto.2019.2723.
13. Kim, D. H., Kim, S. W., Han, J. S., Kim, G. J., Park, J. H., Basurrah, M. A., Kim, S. H., & Hwang, S. H. (2024). Comparative effectiveness of hypoglossal nerve stimulation and alternative treatments for obstructive sleep apnea: A systematic review and meta-analysis. *Journal of Sleep Research*, 33(3), e14017. <https://doi.org/10.1111/jsr.14017>
14. Kompelli, A.R., Ni, J.S., Nguyen, S.A., Lentsch, E.J., Neskey, D.M., & Meyer, T.A. (2018, Sept). The outcomes of hypoglossal nerve stimulation in the management of OSA: A systematic review and meta-analysis. *World J Otorhinolaryngol Head Neck Surg*, 5(1), 41-48. doi: 10.1016/j.wjorl.2018.04.006.
15. Lee, J. J., & Sundar, K. M. (2021). Evaluation and management of adults with obstructive sleep apnea syndrome. *Lung*, 199(2), 87-101.
16. Mashaqi S, Patel SI, Combs D, et al. The Hypoglossal Nerve Stimulation as a Novel Therapy for Treating Obstructive Sleep Apnea—A Literature Review. *Int J Environ Res Public Health*. 2021 Feb; 18(4): 1642. doi: 10.3390/ijerph18041642
17. Philip, P., Heiser, C., Bioulac, S., et al. (2018). Hypoglossal nerve stimulation on sleep and level of alertness in OSA: A preliminary study. *Neurology*, 91(7), e615-e619. DOI: 10.1212/WNL.0000000000006001
18. Randerath W, Verbraecken J, de Raaff CAL, et al. European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea. *Eur*. 2021;30(162):31.
19. Schwartz, A. R., Jacobowitz, O., Eisele, D. W., Mickelson, S. A., Miller, M. B., Oliven, A., ... & Maurer, J. T. (2023). Targeted hypoglossal nerve stimulation for patients with obstructive sleep apnea: a randomized clinical trial. *JAMA Otolaryngology–Head & Neck Surgery*, 149(6), 512-520.

20. U.S. Food & Drug Administration. (2014). INSPIRE II UPPER AIRWAY STIMULATOR. FDA Premarket Approval (PMA) number P130008, Decision Date April 30, 2014.
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130008>
21. U.S. Food & Drug Administration. (2017). Inspire System Implant Manual Model 3028, 4063, 4340. Premarket Approval (PMA) number P130008 Supplement Number S016, Decision date May 5, 2017. https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130008S039C.pdf
22. U.S. Food & Drug Administration. (2019). Stimulator, Hypoglossal Nerve, Implanted, Apnea. Premarket Approval (PMA) number P130008 Supplement Number S038, Decision date Jan 9, 2019. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130008S038>
23. U.S. Food & Drug Administration. (2023). Inspire Upper Airway Stimulation System. Premarket Approval (PMA) number P130008 Supplement Number S090. Decision date June 8, 2023.
<https://www.fda.gov/medical-devices/recently-approved-devices/inspire-upper-airway-stimulation-p130008s090>
24. Weaver, E.M., Kapur, V.K. (2021). *Surgical treatment of obstructive sleep apnea in adults*. UpToDate.com. Last updated May 14, 2021. Retrieved June 17, 2021 from
<https://www.uptodate.com/contents/surgical-treatment-of-obstructive-sleep-apnea-in-adults>
25. Woodson, B. T., Strohl, K. P., Soose, R. J., Gillespie, M. B., Maurer, J. T., de Vries, N., Padhya, T. A., Badr, M. S., Lin, H. S., Vanderveken, O. M., Mickelson, S., & Strollo, P. J., Jr. (2018). Upper airway stimulation for obstructive sleep apnea: 5-year outcomes. *Otolaryngology–Head and Neck Surgery*, 159(1), 194–202. <https://doi.org/10.1177/0194599818762383>

Clinical Guideline Revision / History Information

Original Date: 8/4/2021

Reviewed/Revised: 12/01/2021, 07/26/2022, 07/19/2023, 07/29/2024, 11/01/2025, 11/02/2026